medRxivGenetic & Genomic MedicinePreprint
Non-additive effects of schizophrenia risk genes reflect convergent downstream function
PJ Michael DeansiD, Carina SeahiD, Jessica JohnsoniD, Judit García‐GonzáleziD, Kayla G. TownsleyiD, Evan Cao, Nadine SchrodeiD, Eli A. StahliD, Paul F. O’ReillyiD, Laura M. HuckinsiD, Kristen BrennandiD
Abstract
Genetic studies of schizophrenia (SCZ) reveal a complex polygenic risk architecture comprised of hundreds of risk variants, the majority of which are common in the population at-large and confer only modest increases in disorder risk. Precisely how genetic variants with individually small predicted effects on gene expression combine to yield substantial clinical impacts in aggregate is unclear. Towards this, we previously reported that the combinatorial perturbation of four SCZ risk genes ("eGenes", whose expression is regulated by common variants) resulted in gene expression changes that were not predicted by individual perturbations, being most non-additive among genes associated with synaptic function and SCZ risk. Now, across fifteen SCZ eGenes, we demonstrate that non-additive effects are greatest within groups of functionally similar eGenes. Individual eGene perturbations reveal common downstream transcriptomic effects ("convergence"), while combinatorial eGene perturbations result in changes that are smaller than predicted by summing individual eGene effects ("sub-additive effects"). Unexpectedly, these convergent and sub-additive downstream transcriptomic effects overlap and constitute a large proportion of the genome-wide polygenic risk score, suggesting that functional redundancy of eGenes may be a major mechanism underlying non-additivity. Single eGene perturbations likewise fail to predict the magnitude or directionality of cellular phenotypes resulting from combinatorial perturbations. Overall, our results indicate that polygenic risk cannot be extrapolated from experiments testing one risk gene at a time and must instead be empirically measured. By unravelling the interactions between complex risk variants, it may be possible to improve the clinical utility of polygenic risk scores through more powerful prediction of symptom onset, clinical trajectory, and treatment response, or to identify novel targets for therapeutic intervention.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: benchmarking
- approach: statistical model
- approach: experimental assay
- Citations
- 9
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Convergent and non-additive impact of schizophrenia risk genes in human neurons
PJ Michael Deans, Kayla G. Townsley, … Kristen Brennand·bioRxiv·Mar 29, 2022
- Polygenic risk score for schizophrenia is not strongly associated with the expression of specific genes or gene sets
David Curtis·Psychiatric GeneticsPeer-reviewed·Apr 18, 2018
- Penetrance and pleiotropy of polygenic risk scores for schizophrenia in 106,160 patients across four healthcare systems
Amanda B. Zheutlin, Jessica Kiri Dennis, … Jordan W. Smoller·American Journal of PsychiatryPeer-reviewed·Aug 16, 2019
- Identifying modifiable comorbidities of schizophrenia by integrating electronic health records and polygenic risk
Tess Vessels, Nick Strayer, … Douglas M. Ruderfer·medRxiv·Jun 1, 2023
- Investigating the role of behaviour in the genetic risk for schizophrenia
Jessye M. Maxwell, Adam Socrates, … Paul F. O’Reilly·bioRxiv·Apr 18, 2019
- Genetic combination risk for schizophrenia
Kengo Oishi, Tomihisa Niitsu, … Masaomi Iyo·Schizophrenia ResearchPeer-reviewed·Aug 30, 2019